Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains

被引:1
作者
Li-Hui Wang
机构
关键词
Helicobacter pylori; Antibiotic resistance; Quinolones; Mutation; gyrA;
D O I
暂无
中图分类号
R378 [病原细菌];
学科分类号
100103 ; 100705 ;
摘要
AIM:To investigate the resistance of Helicobacter pylori(H.pylori) to ciprofloxacin(CIP),levofloxacin(LVX) and moxifloxacin(MOX) in the Beijing area and to elucidate the resistance mechanisms.METHODS:Seventy-nine H.pylori clinical strains,isolated from patients who had undergone upper gastrointestinal endoscopy in Peking University First Hospital from 2007 to 2009,were tested for their susceptibility to CIP,LVX and MOX using the E-test method.H.pylori strain 26695 was included in the susceptibility testing as a control strain.According to the minimal inhibitory concentration(MIC) values,a strain was classified as resistant to CIP,LVX or MOX when the MIC was > 1 μg/mL.We amplified by polymerase chain reaction(PCR) and sequenced the quinolone resistance-determining regions of the gyrA and gyrB genes from 29 quinolone-resistant and 16 quinolone-susceptible H.pylori strains selected at random.RESULTS:In this study,the resistance rates of H.pylori to CIP,LVX or MOX were 55.7%(44/79),and the primary resistance rates were 26.6%(21/79).Patients with secondary resistance had received LVX in previous eradication treatments,but not MOX or CIP.Forty-five strains,including 29 CIP,LVX or MOX-resistant strains(MIC:1.5-32 μg/mL) and 16 susceptible strains,were selected randomly from the 79 strains and used in PCR analysis.Among these 45 strains,27 resistant strains had mutations in the gyrA gene,including 11 strains with mutations corresponding to Asp-91(MIC:2-32 μg/mL),one of which also had a mutation corresponding to Val-150,and 16 strains had mutations at Asn-87(MIC:4-32 μg/mL),three of which also had mutations corresponding to Arg-140 or Val-150.In addition,Arg-140,Val-150 or Ala-97 mutations were separately detected in three susceptible strains.Analysis of the gyrB gene showed that one strain of low resistance had a mutation corresponding to Ser-457 that coexisted with an Asp-91 mutation.There was a significant difference in the occurrence of mutations in the gyrA gene between CIP,LVX and MOX-resistant and-susceptible strains(P < 0.05),but 2 resistant strains were found to possess no quinolone resistance-determining region mutations.CONCLUSION:Resistance is primarily mediated through point mutations in gyrA.Whether other mechanisms are responsible for resistance in strains without mutations in the QRDR should be detected.
引用
收藏
页码:2272 / 2277
页数:6
相关论文
共 9 条
[1]   喹诺酮类抗生素临床应用态势及合理用药 [J].
冉启文 .
中国医药指南, 2009, 7 (12) :41-43
[2]   喹诺酮类抗菌药在外科感染中的应用 [J].
黎沾良 ;
陈惠德 ;
汤耀卿 .
中国感染与化疗杂志, 2009, 9 (02) :97-98
[3]   中国幽门螺杆菌耐药状况以及耐药对治疗的影响—全国多中心临床研究 [J].
成虹 ;
胡伏莲 ;
谢勇 ;
胡品津 ;
王吉耀 ;
吕农华 ;
张建中 ;
张桂英 ;
周曾芬 ;
吴克利 ;
张玲霞 ;
彭孝伟 ;
戴宁 ;
唐国都 ;
姜葵 ;
李岩 ;
侯晓华 ;
白文元 ;
王明春 ;
叶红军 ;
刘玉兰 ;
许乐 .
胃肠病学, 2007, (09) :525-530
[4]  
Third-line rescue therapy for Helicobacter pylori infection[J]. Rossella Cianci,Massimo Montalto,Franco Pandolfi,Giovan Battista Gasbarrini,Giovanni Cammarota.World Journal of Gastroenterology. 2006(15)
[5]   A five-year follow-up study on the pathological changes of gastric mucosa after H.pylori eradication [J].
周丽雅 ;
沈祖尧 ;
林三仁 ;
金珠 ;
丁士刚 ;
黄雪彪 ;
夏志伟 ;
郭慧兰 ;
刘建军 ;
曹世植 .
Chinese Medical Journal, 2003, (01)
[6]  
A double mutation in the gyrA gene is necessary to produce high levels of resistance to moxifloxacin in Campylobacter spp. clinical isolates[J] . Joaquim Ruiz,Asunción Moreno,M. Teresa Jimenez de Anta,Jordi Vila.International Journal of Antimicrobial Agents . 2005 (6)
[7]   High-frequency of quinolone-resistant Neisseria gonorrhoeae in Austria with a common pattern of triple mutations in GyrA and ParC genes [J].
Uthman, A ;
Heller-Vitouch, C ;
Stary, A ;
Bilina, A ;
Kuchinka-Koch, A ;
Söltz-Szöts, J ;
Tschachler, E .
SEXUALLY TRANSMITTED DISEASES, 2004, 31 (10) :616-618
[8]   Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy' [J].
Perri, F ;
Festa, V ;
Merla, A ;
Barberani, F ;
Pilotto, A ;
Andriulli, A .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 (08) :815-820
[9]  
Mono, dual and triple moxifloxacin‐based therapies for Helicobacter pylori eradication[J] . S.Di Caro,V.Ojetti,M. A.Zocco,F.Cremonini,F.Bartolozzi,M.Candelli,A.Lupascu,E. C.Nista,G.Cammarota,A.Gasbarrini.Alimentary Pharmacology & Therapeutics . 2002 (3)